TRT and Bone Density: Does Testosterone Therapy Strengthen the Skeleton?

This distinction has concrete, not just academic, implications: men on TRT who are also prescribed an aromatase inhibitor (a drug that blocks the conversion of testosterone to estradiol, sometimes used to control estrogen levels) may genuinely limit the bone benefit of therapy, even if their blood testosterone level is high. Below, we explain this two-step mechanism, what a controlled clinical trial measuring volumetric bone density actually found, and for whom this effect has real clinical relevance — and for whom it doesn't.

Osteoblasts — the cells responsible for building new bone tissue — carry androgen receptors, as do osteocytes, the mature bone cells embedded in the bone matrix that act as sensors of mechanical load on the skeleton. Testosterone, by binding the androgen receptor in these cells, stimulates osteoblast activity and promotes periosteal apposition — the laying down of new bone tissue on a bone's outer surface, which increases its cross-sectional dimensions and mechanical strength, especially in cortical (compact) bone, the dense outer shell of most long bones.

This direct androgen pathway partly explains why men typically have wider, more massive bones than women at a comparable age and height — an effect of androgen-driven periosteal growth during puberty and early adulthood that persists to some degree throughout life at normal testosterone levels. In men with hypogonadism, where this signal is chronically weaker, cortical bone tends to be relatively narrower and mechanically weaker, independent of the mineral density of the tissue itself.

This is the least intuitive, yet most important, part of the mechanism. Testosterone is converted to estradiol by the enzyme aromatase, present in fat tissue among other places, but also locally within bone itself. In men, it's estradiol — not testosterone — that's the main hormonal regulator of bone resorption, the process by which osteoclasts break down and absorb bone tissue. The evidence for this is fairly dramatic: men with a rare congenital aromatase deficiency, whose testosterone levels can be normal or even elevated but whose bodies can't convert it to estradiol, develop severe osteoporosis at a young age — despite normal, sometimes high, testosterone itself.

This dependence on conversion to estradiol has practical relevance for patients on TRT who are also prescribed an aromatase inhibitor, for instance to control gynecomastia or elevated estradiol. Blocking the conversion of testosterone to estradiol could theoretically limit the bone benefit of testosterone therapy, even when blood testosterone itself is adequately high — one argument for very cautious, minimal use of aromatase inhibitors, especially in men with additional fracture risk factors.

The effect observed in the Testosterone Trials applies to a specific, defined group: older men with confirmed, low testosterone. It isn't evidence that testosterone therapy is an effective, general treatment for osteoporosis in men with normal testosterone levels — in such patients, there's no basis for using TRT solely because of low bone density, and standard osteoporosis medications (bisphosphonates, denosumab, and others) remain the first-line treatment regardless of androgen levels.

The group for whom this effect carries real clinical weight is men with confirmed hypogonadism and additional fracture risk factors — for example, a prior low-energy fracture, low bone density on a DEXA scan, or other established osteoporosis risk factors. In this group, correcting a testosterone deficiency may be one element of a broader skeletal-protection strategy, alongside adequate calcium and vitamin D intake, weight-bearing physical activity, and, where indicated, dedicated osteoporosis treatment.

A second, less often discussed myth concerns the mechanism itself: many patients assume it's „testosterone as such” that strengthens bone, while evidence from congenital aromatase-deficiency research indicates that a significant part of this effect in men depends on testosterone's conversion to estradiol. That's not a trivial detail — it has real implications for decisions about using aromatase inhibitors as part of a TRT protocol.

This is one of those topics where the mechanism itself is more interesting, and more important, than the simple headline „testosterone strengthens bones.” The real picture — a two-step mechanism where much of the benefit depends on conversion to estradiol — has direct relevance for clinical decisions, especially for patients also taking aromatase inhibitors. For most men on TRT, bone density shouldn't be the main reason to start therapy, but for those with confirmed hypogonadism and additional fracture risk factors, it's a real, worth-considering additional benefit.